Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
First and only PARP inhibitor to improve invasive disease-free survival in patients
Subscribe To Our Newsletter & Stay Updated
